Find an expert

Gabrielle Belz originally trained in veterinary medicine and surgery and received her PhD in understanding the organisation of lymphatics and lymphoid tissues at The University of Queensland. After a short stint in Canada to work on B cells, she moved to St Jude Children’s Research Hospital to work with Peter Doherty supported by an NHMRC CJ Martin Fellowship. Here she established a number of systems that now allow tracking of virus-specific T cells and established the paradigm changing notion that CD4 T cell help was required for generating antiviral responses. She returned to The Walter and Eliza Hall Institute of Medical Research and uncovered the identity of the key dendritic cells necessary for initiating antiviral infections. Subsequently she was awarded the Burnet Prize and NHMRC Elizabeth Blackburn Fellowship. Her research contributions have been recognized by a number of awards including a Wellcome Trust Overseas Fellowship, HHMI international fellowship, ARC Future fellowship, Doctor of Veterinary Science, the Gottschalk Medal (Australian Academy of Science) and in 2024 an ARC Laureate Fellowship. Her laboratory focuses on deciphering the key cellular and transcriptional signals of protective immunity particularly by T cells and in understanding how innate immune cells develop and make novel contributions to mucosal immune defence.

Dr Andrew Brooks is the Group Leader of the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute (UQ DI) within the Translational Research Institute. Andrew completed his Honours research on Flaviviruses in 1996 at the Department of Microbiology and Immunology at James Cook University and then moved to the Department of Biochemistry to study Dengue Virus where he completed his PhD in 2002. He then moved to St Jude Children’s Research Hospital in Memphis, TN, USA where he researched the role of Epstein-Barr Virus in B-cell lymphomagenesis. He then joined the research group headed by Prof Michael Waters at the Institute for Molecular Bioscience, UQ in 2006 and subsequently began his independent research group at UQ DI in 2014. Andrew’s research interests are in cytokine receptors, cell signalling, oncogenesis, and immunology. His current research focus is on the molecular mechanisms of class I cytokine receptor activation including the growth hormone receptor (GHR), thrombopoietin receptor (TpoR/MPL), IL-7 receptor, and IL-6 receptor (IL-6R). In addition, he is investigating the regulation of inflammation by HLA-G. His research has led to publications in journals including Science, Blood, Hepatology, Oncogene, Nature Cell Biology, and PNAS. He has been the secured of over $12 million in research and commercialisation funding from sources including NHMRC, ARC, Innovation Connections, and Merck. He has a number of national and international collaborations, a scientific founder of a start-up company, and is an Editorial Board member for the Journal Cancers and Human Cell. He was previously a committee member of Australian Early-Mid Career Researchers Forum (AEMCRF) launched by the Australian Academy of Science.

Dr Jenny Fung is a senior postdoctoral research fellow and lecturer of pharmacology course at the School of Biomedical Sciences (SBMS), UQ. She is an emerging researcher in the reproductive disease field with experience in molecular biology techniques, genetics, functional genomics, statistical and high-throughput computational skills, ex-vivo and in-vivo models of diseases, as well as industry engagement. In 2013, she was awarded a PhD at UQ and continued post-doctoral research in Professor Grant Montgomery's laboratory at QIMRB and IMB, in the field of genetics and genomics with a focus on functional genomics studies in complex diseases and a special interest in endometriosis. Her research has led to the seminal publication identifying the genetics of gene expression in endometrium and the role of gene regulation underlying endometriosis-related pathogenesis. In 2019, she joined Professor Trent Woodruff’s laboratory at SBMS, UQ to work on immunotherapy development for cancer through funding from Pfizer, where she performed immune cell functional assays and genomics analyses. Dr Fung is in a unique position to perform both the wet and dry lab components of multi-disciplinary research. She is currently co-leading multiple projects, where she is contributing her expertise on genetics and functional genomics on immunology to discover target genes and putative pathways underlying disease progression, with an ultimate goal to develop potential effective drugs for reproductive and brain disorders.

Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.

Over 5 years of experience in translational biomedical research, specialising in monoclonal antibody-based therapies, immuno-oncology, target discovery and theranostics in cancer. My main research focus is on targeted cancer therapies, understanding how target receptor endocytosis affects antibody drug conjugate (ADC) and radioligand therapy delivery, immune-mediated ADCC, and how combination therapies with immune checkpoint inhibitors can potentially improve therapeutic outcomes for patients.

Dr Natacha Omer is a paediatic oncologist at the Queensland Children's Hospital in Brisbane. She is specialised in solid tumours, with a spacial interest in paediatric and adolescent sarcomas, cancer immunotherapy and molecular oncology. She is undertaking a PhD in immunology studying natural killer (NK) cell immunotherapy in paediatric sarcomas at the Frazer Institute, University of Queensland, in Dr Fernando Guimaraes lab.

A/Prof Barbara Rolfe is a Group Leader at the Australian Institute for Bioengineering and Nanotechnology. A/Prof Rolfe is an immunologist and cell biologist, whose major research interests are the role of the innate immune system in cancer, the identification of novel therapeutic strategies for cancer, and nanomaterial safety. Her research has led to the identification of a previously unknown mechanism by which dysregulation of the immune system contributes to cancer development and growth, and provided information regarding the immune response to nanomaterials and the influence of physicochemical characteristics on biodistribution and cellular uptake. A/Prof Rolfe has used mouse models and small peptide agonists and antagonists to investigate the role of the innate immune system in tumour development and growth. This research demonstrated for the first time an important role for complement proteins in promoting tumour growth via regulation of immunosuppressive innate immune cells. Ongoing research is aimed focussed on gaining a better understanding of the role of complement proteins in tumour growth, developing novel immunotherapeutic strategies for cancer and investigating the application of nanomaterials for targeted delivery of anti-cancer drugs.

Dr. Kelvin Tuong is a Senior Research Fellow/Group Leader at the Ian Frazer Centre for Children’s Immunotherapy Research (IFCCIR), Child Health Research Centre. He is interested in single-cell analysis of immune cells and harnessing adaptive immune receptors for understanding immune cell development and function in health and in cancer.

Dr. Tuong was born and raised in Singapore and moved to Brisbane, Australia, after completing national service in Singapore and obtaining a Diploma in Biomedical Laboratory Technology (Ngee Ann Polytechnic).

Dr. Tuong was originally trained as a molecular cell biologist and gradually transitioned into bioinformatics during his post-doctoral training. He has been very prolific for an early career researcher, having published >50 articles since 2013, with nearly a third of them as first/co-first or last author and has a stellar track record of pushing out highly collaborative work in prestigious journals including Nature, Cell, Science, Nature Medicine, Nature Biotechnology J Exp Med etc. He has the rare combination of having excellent laboratory and bioinformatics skill sets which provide him a strong command of both fundamental immunology and computational approaches.

Dr. Tuong completed his undergraduate Bachelor's degree in Biomedical science with Class I Honours, followed by his PhD in macrophage cell biology and endocrinology at UQ (Prof. Jenny Stow lab and Emiritus Prof. George Muscat lab, IMB, UQ). He then went on to a post-doc position with Emiritus Prof. Ian Frazer (co-inventor of the Gardasil cervical cancer vaccine, UQ Frazer Institute, Translational Research Institute) where he worked on HPV immunology, cervical cancer and skin cancer. In his time in the Frazer lab, he developed an interest in bioinformatics analyses as a means to tackle and understanding immunology problems in health and disease. He then moved to the UK and joined Prof. Menna Clatworthy's lab at the University of Cambridge and Dr. Sarah Teichmann's lab at the Wellcome Trust Sanger Institute. He has focused his interests on single-cell analyses of tissue immune cells, including T and B cells and their specific receptors (TCR/BCR). He has developed bespoke bioinformatics software, including one tailored for single-cell B Cell Receptor sequencing analysis, Dandelion, which he used in one of the largest combined single-cell transcriptomic, surface proteomic and TCR/BCR sequencing dataset in the world, published in Nature Medicine, and more recently in Nature Biotechnology where we introduced a TCR-based pseudotime trajectory analysis method.

Dr. Tuong is now leading the Computational Immunology group at the IFCCIR and his lab is focused on investigating how pediatric immunity is perturbed during cancer at the cellular level and how this information can be used for creating novel warning systems for children with cancer. For potential students/post-docs/trainees interested in joining the team, please contact Dr. Tuong at z.tuong@uq.edu.au.